256 related articles for article (PubMed ID: 26208921)
21. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
[TBL] [Abstract][Full Text] [Related]
22. A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritis.
Schlueter M; Rouse P; Pitcher A; Graham-Clarke PL; Nicolay C; Fakhouri W
Expert Rev Pharmacoecon Outcomes Res; 2020 Apr; 20(2):221-228. PubMed ID: 32212867
[No Abstract] [Full Text] [Related]
23. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
24. Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling.
Williams C; Lewsey JD; Mackay DF; Briggs AH
Med Decis Making; 2017 May; 37(4):427-439. PubMed ID: 27698003
[TBL] [Abstract][Full Text] [Related]
25. Calculating when elective abdominal aortic aneurysm repair improves survival for individual patients: development of the Aneurysm Repair Decision Aid and economic evaluation.
Grant SW; Sperrin M; Carlson E; Chinai N; Ntais D; Hamilton M; Dunn G; Buchan I; Davies L; McCollum CN
Health Technol Assess; 2015 Apr; 19(32):1-154, v-vi. PubMed ID: 25924187
[TBL] [Abstract][Full Text] [Related]
26. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
27. Drug-eluting stents: a systematic review and economic evaluation.
Hill RA; Boland A; Dickson R; Dündar Y; Haycox A; McLeod C; Mujica Mota R; Walley T; Bagust A
Health Technol Assess; 2007 Nov; 11(46):iii, xi-221. PubMed ID: 17999841
[TBL] [Abstract][Full Text] [Related]
28. Markov modeling for the neurosurgeon: a review of the literature and an introduction to cost-effectiveness research.
Wali AR; Brandel MG; Santiago-Dieppa DR; Rennert RC; Steinberg JA; Hirshman BR; Murphy JD; Khalessi AA
Neurosurg Focus; 2018 May; 44(5):E20. PubMed ID: 29712528
[TBL] [Abstract][Full Text] [Related]
29. Decision-analytic modeling for early health technology assessment of medical devices - a scoping review.
Conrads-Frank A; Schnell-Inderst P; Neusser S; Hallsson LR; Stojkov I; Siebert S; Kühne F; Jahn B; Siebert U; Sroczynski G
Ger Med Sci; 2022; 20():Doc11. PubMed ID: 36742459
[TBL] [Abstract][Full Text] [Related]
30. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
31. Minimally invasive surgical procedures for the treatment of lumbar disc herniation.
Lühmann D; Burkhardt-Hammer T; Borowski C; Raspe H
GMS Health Technol Assess; 2005 Nov; 1():Doc07. PubMed ID: 21289928
[TBL] [Abstract][Full Text] [Related]
32. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
33. Modeling complex treatment strategies: construction and validation of a discrete event simulation model for glaucoma.
van Gestel A; Severens JL; Webers CA; Beckers HJ; Jansonius NM; Schouten JS
Value Health; 2010; 13(4):358-67. PubMed ID: 20659272
[TBL] [Abstract][Full Text] [Related]
34. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
35. Generalisability in economic evaluation studies in healthcare: a review and case studies.
Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A
Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708
[TBL] [Abstract][Full Text] [Related]
36. Decision-Analytic Modeling Studies in Prevention and Treatment of Iodine Deficiency and Thyroid Disorders: A Systematic Overview.
Rochau U; Qerimi Rushaj V; Schaffner M; Schönhensch M; Stojkov I; Jahn B; Hubalewska-Dydejczyk A; Erlund I; Thuesen BH; Zimmermann M; Moreno-Reyes R; Lazarus JH; Völzke H; Siebert U
Thyroid; 2020 May; 30(5):746-758. PubMed ID: 31964247
[No Abstract] [Full Text] [Related]
37. Small class sizes for improving student achievement in primary and secondary schools: a systematic review.
Filges T; Sonne-Schmidt CS; Nielsen BCV
Campbell Syst Rev; 2018; 14(1):1-107. PubMed ID: 37131395
[TBL] [Abstract][Full Text] [Related]
38. Evaluating Cost-Effectiveness Models for Pharmacologic Interventions in Adults with Heart Failure: A Systematic Literature Review.
Di Tanna GL; Bychenkova A; O'Neill F; Wirtz HS; Miller P; Ó Hartaigh B; Globe G
Pharmacoeconomics; 2019 Mar; 37(3):359-389. PubMed ID: 30596210
[TBL] [Abstract][Full Text] [Related]
39. When to use discrete event simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES.
Karnon J; Haji Ali Afzali H
Pharmacoeconomics; 2014 Jun; 32(6):547-58. PubMed ID: 24627341
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
